Abstract
Background: Coronavirus disease 2019, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has wreaked havoc worldwide since December 2019. Currently, no effective medical treatments have been approved. As the epidemic continues to spread, SARS-CoV-2 mutants emerge, some of which become more infectious with increasing vaccine resistance. The main route for SARS-CoV-2 to enter the host cells is by binding its spike protein to the host receptor, angiotensin-converting enzyme 2 (ACE2). Besides the membrane-bound form of ACE2, the soluble form of ACE2 (sACE2) can also bind SARS-CoV-2 for viral endocytosis.
Objective: Previously, we found that telbivudine reduced the concentrations of ACE1 in blood. Therefore, we speculated that this drug might also reduce the concentrations of sACE2.
Methods: In this retrospective study, serum samples from 39 hepatitis B patients receiving telbivudine were collected and examined for sACE2 concentrations using an ELISA kit..
Results: It was found that the serum concentrations of sACE2 were significantly declined in chronic hepatitis B patients treated with telbivudine.
Conclusion: Telbivudine treatment reduced sACE2 concentrations, which could potentially reduce the infection risk of SARS-CoV-2.
Keywords: Coronavirus disease 2019, severe acute respiratory syndrome coronavirus 2, angiotensin-converting enzyme, telbivudine, hepatitis B virus, serum, SARS-CoV-2, ACE2.
[http://dx.doi.org/10.2174/156652405774641124] [PMID: 16305493]
[http://dx.doi.org/10.1016/S1473-3099(20)30484-9] [PMID: 32628905]
[http://dx.doi.org/10.1016/j.molmed.2020.02.008] [PMID: 32359479]
[http://dx.doi.org/10.1007/s00408-020-00408-4] [PMID: 33170317]
[http://dx.doi.org/10.1161/JAHA.120.016219] [PMID: 32233755]
[http://dx.doi.org/10.1007/s11906-014-0420-5] [PMID: 24510672]
[http://dx.doi.org/10.3390/ijms22136703] [PMID: 34201415]
[http://dx.doi.org/10.1016/j.cell.2021.02.053] [PMID: 33713620]
[http://dx.doi.org/10.1038/s41392-022-00913-3] [PMID: 35140198]
[http://dx.doi.org/10.1016/j.clinthera.2007.12.032] [PMID: 18201580]
[http://dx.doi.org/10.1053/j.gastro.2013.09.031] [PMID: 24067879]
[http://dx.doi.org/10.5009/gnl16484] [PMID: 28651305]
[http://dx.doi.org/10.5812/hepatmon.15074] [PMID: 24596580]
[http://dx.doi.org/10.1073/pnas.2016093117] [PMID: 33093202]
[http://dx.doi.org/10.3390/molecules26010057] [PMID: 33374387]
[http://dx.doi.org/10.1038/s42003-021-01736-8] [PMID: 33580154]
[http://dx.doi.org/10.1016/j.imu.2021.100531] [PMID: 33594342]
[http://dx.doi.org/10.1080/10799893.2020.1772298] [PMID: 32476594]
[http://dx.doi.org/10.3390/molecules26247458] [PMID: 34946540]
[http://dx.doi.org/10.3390/biomedicines9080996] [PMID: 34440200]